Sanofi has reported Phase II data for a new drug candidate for lowering cholesterol levels in patients already taking statins. Over an 8-12 week period, the candidate reduced low density lipoprotein (LDL) cholesterol - so-called ’bad’ cholesterol - by 40-72%, compared with 5% for placebo treatment. The 183 patients in ...